Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS (GLUT-HEP)
Phase of Trial: Phase II
Latest Information Update: 05 Apr 2018
At a glance
- Drugs Triheptanoin (Primary)
- Indications De Vivo disease
- Focus Therapeutic Use
- Acronyms GLUT-HEP
- 30 Apr 2015 Planned End Date changed from 1 Nov 2014 to 1 Apr 2018 as reported by ClinicalTrials.gov record.
- 30 Apr 2015 Planned primary completion date changed from 1 Nov 2014 to 1 May 2015 as reported by ClinicalTrials.gov record.
- 22 Apr 2015 According to Ultragenyx media release, the company is planning to initiate a confirmatory study based on the results of this trial.